Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Genomic Health, Inc.    GHDX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/09/2017 01/10/2017 01/11/2017 01/12/2017 01/13/2017 Date
29.2(c) 29.7(c) 28.77(c) 28.98(c) 29.25(c) Last
205 492 133 860 165 551 135 466 111 606 Volume
-0.75% +1.71% -3.13% +0.73% +0.93% Change
More quotes
Financials ($)
Sales 2016 329 M
EBIT 2016 -16,9 M
Net income 2016 -15,3 M
Finance 2016 43,4 M
Yield 2016 -
Sales 2017 364 M
EBIT 2017 3,74 M
Net income 2017 3,20 M
Finance 2017 54,6 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 308,54
EV / Sales2016 2,84x
EV / Sales2017 2,54x
Capitalization 979 M
More Financials
Company
Genomic Health, Inc. is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions.The company has a robust pipeline focused on developing tests to optimize the treatment of renal cell cancers, as well as additional treatment decisions in... 
More about the company
Surperformance© ratings of Genomic Health, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on GENOMIC HEALTH, INC.
01/03 GENOMIC HEALTH : to Present at the 35th Annual J.P. Morgan Healthcare Conference
2016 GENOMIC HEALTH : Announces Inclusion of Oncotype DX® in the 8th Edition of Ameri..
2016 GENOMIC HEALTH INC : Change in Directors or Principal Officers (form 8-K)
2016 GENOMIC HEALTH : Announces Results from Multiple Oncotype DX® Studies, Reinforci..
2016 GENOMIC HEALTH : Announces Results from Multiple Oncotype DX® Studies, Reinforci..
2016 GENOMIC HEALTH : Announces Presentation of Multiple Oncotype DX® Studies at the ..
2016 GENOMIC HEALTH : Announces Positive Topline Clinical Validation Study Results De..
2016 GENOMIC HEALTH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
2016 GENOMIC HEALTH : to Present at the Credit Suisse 25th Annual Healthcare Conferen..
2016 GENOMIC HEALTH : reports 3Q loss
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/09Genomic Health's sell rating reiterated at Barclays PLC. $27.00 PT.  
01/07$GHDX - Laurion Capital Management LP Buys New Stake in Genomic Health, Inc. .. 
01/04$GHDX downgraded to Market Perform From Outperform at Cowen 
01/04Genomic Health downgraded by Cowen and Company to market perform.  
01/03Genomic Health : to Present at the 35th Annual J.P. Morgan Healthcare Confere.. 
More tweets
Qtime:60
News from SeekingAlpha
2016 Genomic Health's Oncotype DX test included in latest cancer staging manual
2016 Genomic Health shoots a few holes in Myriad-quoted study
2016 Myriad's breast cancer test beats Genomic Health's in head-to-head study
2016 Genomic Health's (GHDX) CEO Kim Popovits on Q3 2016 Results - Earnings Call T..
2016 Genomic Health beats by $0.01, misses on revenue
Advertisement
Chart GENOMIC HEALTH, INC.
Duration : Period :
Genomic Health, Inc. Technical Analysis Chart | GHDX | US37244C1018 | 4-Traders
Full-screen chart
Technical analysis trends GENOMIC HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 31,9 $
Spread / Average Target 9,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kimberly J. Popovits Chairman, President & Chief Executive Officer
G. Bradley Cole Chief Operating & Financial Officer
Steven Shak Chief Scientific Officer
Phillip G. Febbo Chief Medical Officer
Amy P. Sing Senior Director-Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GENOMIC HEALTH, INC.-0.48%979
INCYTE CORPORATION17.43%22 182
QUINTILES IMS HOLDINGS..1.46%18 995
CELLTRION, INC.--.--%10 650
LONZA GROUP AG5.05%9 643
ALKERMES PLC-0.22%8 428
More Results